Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2022-11-18 00:00:00 ET · period of report 2022-11-17 · accession 0001209191-22-057823 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-18 | 2022-11-17 | CBIO | JUNIUS DANIEL M | Dir | P - Purchase | $1.87 | +20.0K | 63.2K | +46% | +$37.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-17 | P | A | 20,000 | $1.87 | 63,250 | D | — | — | (F1) The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.855 to $1.89 per share, with a weighted average purchase price of $1.87 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |